I
t is fairly well accepted now that the best evidence for demonstrating that an intervention works comes from the results of a randomized controlled trial (RCT), in which eligible patients are randomly assigned to either a new therapy or to a comparison group. However, there are RCTs, and then there are RCTs. In other words, not all RCTs are the same. In this article, we will discuss the differences between RCTs designed to demonstrate the effectiveness of treatment and those that look at the efficacy of an intervention. Thus, it's first necessary to discuss the difference between efficacy and effectiveness.
Efficacy is concerned with the question, Can a treatment work under ideal circumstances? Conversely, effectiveness addresses the question, Does it work in the real world? Studies that focus on efficacy do everything possible to maximize the chances of showing an effect. The rationale is that if the treatment cannot be shown to work under the best conditions, there isn't a ghost of a chance that it will be effective in actual practice. On the other hand, effectiveness studies emphasize the applicability of the treatment and therefore try harder to duplicate the situations that clinicians will encounter in their practices. The 2 study types are referred to in terms that describe their differing aims and designs. They are sometimes distinguished as explanatory and pragmatic trials (1, 2) ; at other times they are called explanatory and management trials (3) . "Pragmatic" and "management" capture the flavour of the question, Do things work in the real world? However, "explanatory" is a bit misleading, because the emphasis in the study is more on "can" than on "why." So, I'll continue to use the terms efficacy and effectiveness in this paper.
No matter what they're called, though, the difference between the 2 types has implications for who is selected to be in the study, how the intervention is delivered, how dropouts and people who receive the "wrong" treatment are handled, and how the results are analyzed. In actuality, efficacy and effectiveness studies are the extremes of a continuum, and most studies fall somewhere in between. However, it is important for the reader of trials to be aware of these implications, because they affect (or should affect) how the results are interpreted: do you change your clinical practice today, in light of the findings, or do you wait until more convincing evidence is in?
To illustrate the difference, I will focus on the treatment of a disorder that Geoff Norman and I discovered several years ago: photonumerophobia, or the fear that one's fear of numbers will come to light (4, 5 Studies that investigate the usefulness of various therapies fall along a continuum that ranges from those looking at whether an intervention can work under ideal circumstances (efficacy trials) to those that focus on whether a treatment works when applied in the real world (effectiveness trials). Whether a study is closer to one end of the spectrum or the other affects almost every aspect of the trial. These aspects include which patients are eligible for enrolment, the degree of control over the way the intervention is delivered, which patients are or are not included in the analyses, how missing data are handled, and even which statistical tests may be used. The 2 types of trials may yield different results, but both provide useful information. This paper explores these issues, shows the decisions researchers must take at each phase of a trial, and discusses how clinicians should interpret the results. not yet been recognized by DSM or ICD. Nevertheless, after teaching statistics to medical students, nurses, and grad students for more than 3 decades, it is obvious (at least to us) that this is a widely prevalent and disabling condition, but one that is now amenable to treatment. The therapy we propose is teaching statistics using the articles in this "Research Methods in Psychiatry" (RMP) series. To test whether it works, we'll have a comparison group of people treated with another set of readings (the Other condition). The outcome will be the number of people who are not phobic at the end of the semester.
Subject Selection
Most parametric statistical tests, such as the t-test and the analysis of variance (ANOVA), compare how large the difference between the groups is in relation to the variability within groups. That is, they assume that differences among people within the same group is "error" (a better term would perhaps be "unexplained variability") and that the between-group variability must be larger than the within-group variance to show that something is going on. Therefore, when designing a study, we maximize the chances that we'll find a statistically significant result if we 1) make the difference between the groups as large as possible and 2) make the variability within the groups as small as possible. We have relatively little control over the first factor because it's a function primarily of how well the intervention works (although we'll soon see how we can exert that small degree of control). However, we can affect the within-group variability by making the groups as homogeneous as possible in terms of age, sex (to the degree allowed by the granting agencies), other treatments received within a certain time frame, and most important, by ensuring the strictness of the diagnostic criteria and the absence of comorbid disorders. This is why the "subjects" section of efficacy studies begins with a long list of inclusion and exclusion criteria: the criteria exist not only to ensure that the people in the trial actually have the disorder of interest but also to make the groups homogeneous and thus reduce the within-group variability.
Some efficacy studies go even further than making the groups homogeneous: they try to exclude those who may be "placebo responders" and to enrol only those patients who will be most compliant and most responsive to the intervention. For example, some studies use a single-blind run-in phase (6), during which all eligible patients are placed on a placebo. Those who show an improvement are eliminated from the study because they would inflate the change seen in the comparison group and thus reduce the between-group difference. Another tactic is to use an enriched sample (7) of patients who have previously been shown to respond to the intervention. A third approach, used in the Veterans Administration hypertension study, had patients take a riboflavin-labelled placebo (8) . This allowed the investigators to determine which subjects would comply with taking medications and to reject the others.
The drawback of this approach is that the subjects in the study become less and less like the patients encountered in actual practice. The practising clinician does not have the researcher's luxury of saying, "I can't treat your schizophrenia, because DSM-IV says you must have had your symptoms for 6 months, and yours have persisted for only 5 months," or "You also suffer from an anxiety disorder, so out you go." It is also difficult to test whether the patient will be compliant; in any case, the therapist must try to treat the patient even if there are concerns in this regard.
So, if we were designing an efficacy trial of RMP vs Other, we would apply very tight criteria for photonumerophobia and exclude all people who do not meet all of them. We would also reject from the study people who might have other psychological or medical disorders that could lessen the magnitude of the treatment effect or who received some other form of therapy for the problem that would make it difficult to determine what the "active ingredient" was. Conversely, an effectiveness trial would include all people who present with this complaint: all would be accepted for therapy, irrespective of age, comorbidities, or other concurrent therapies. The sample size might have to be increased to compensate for these confounding conditions, but the results would be more generalizable to clinical practice.
The Intervention
I mentioned earlier that the main determinant of the difference between the groups is the effectiveness of the intervention itself and that we have little control over this.
In fact, while we cannot enhance the true effect of the treatment, there are many ways to make it perform less well. Needless to say, efficacy studies try very hard to avoid these pitfalls, using various techniques. From the provider's perspective, these techniques include having therapists attend training sessions so that they can learn to perform the therapy systematically (9), using treatment manuals that detail what should and should not be done during the sessions (10), taperecording the sessions so that they can later be checked for adherence to the treatment protocol (11), having fixed dosing regimens or algorithms in drug trials (12) , or having a fixed number of therapy sessions (13) . Some surgical trials even go so far as to drop surgeons or centres that have high perioperative mortality or infection rates (14) . On the receiving side of the intervention, efficacy studies often have research nurses or assistants call the patients to remind them to take their medication, to reschedule missed appointments, and, sometimes, just to check on the patients between visits.
The advantages of these strategies are obvious. The therapy is delivered either by highly skilled and well-trained people or by advanced students who receive continual supervision and feedback from more senior clinicians. The intervention itself often follows the recommendations of best-practice guidelines, which are (or at least should be) based on the results of earlier clinical trials. When medications are used, a frequent requirement is ongoing monitoring of blood levels to ensure that the medications are within therapeutic levels. Follow-up and reminder calls maximize adherence to the therapy, and these contacts may themselves have some therapeutic effect.
Wouldn't life (or at least work) be wonderful if we all had these resources! The sad reality is that the extra staff and lab work are rarely available or affordable outside large, externally funded RCTs. Further, despite what we read in letters of recommendation, not everybody is in the top 5% of the profession: believe it or not, one-half of the therapists in this world are below average (15) . Even excellent therapists, though, rarely have the luxury of attending week-or month-long training courses after they finish residency or a fellowship. More often, they learn of new techniques through lectures, readings, or, at best, a 1-day preconference workshop that does not have any provision for continuing supervision. The consequence is that therapy in real life is rarely delivered as effectively or uniformly as it is in controlled efficacy trials. Donoghue and Hylan, for example, summarize the results of many surveys showing that in primary and secondary care settings, tricyclic antidepressants are frequently prescribed in dosages lower-often 50% lower-than those found to be efficacious in RCTs (16) .
Effectiveness trials are closer to the end of the continuum that reflects therapy as it is actually given. For example, they impose fewer restrictions on how the treatment is delivered and monitor patient compliance less. Even so, it is rare to see a random selection of clinicians in effectiveness studies: they tend to be drawn from people in academia, often in tertiary care teaching hospitals. It is also becoming increasingly more common for studies of both efficacy and effectiveness to use manualized therapy or drug algorithms; and this is likely more usual in studies than in routine clinical practice. This means that although there is probably still a difference between the way therapy is delivered in effectiveness trials and in real life, these studies tend to be more realistic than are efficacy studies.
Who Gets Counted
Let's assume we have gone through all the steps of finding 100 patients with phobia, allocating them to the 2 groups at random, and carrying out the intervention. At the end of the study, when we start looking at the data, we find that 10 subjects in the Other group have actually stumbled across the RMP series on their own and have read all the articles. In the RMP group, 2 subjects committed suicide before the classes began; 7 dropped out before writing the final exam; and 3 withdrew before the study began, claiming that their phobia was cured. Do we count these people; if so, to which group do we assign the results? That is, are the results of the subjects in the Other group who read the RMP articles attributed to RMP or to Other? The answer is, as one would expect from a statistician-psychologist, "It all depends."
The first thing it depends on is how many people we've lost. Ideally, we've taken measures to keep this number as small as possible, in which case it really won't matter much how we count their results, because it won't appreciably change the results. However, if despite our best efforts we've lost more than roughly 10% to 15% of the subjects, then we have to consider whether we are conducting an efficacy trial or an effectiveness one. If we are asking the question, "Can the intervention work?" (that is, if we are testing its efficacy), then we are in a bit of a bind. We can argue on the one hand that it doesn't make sense to blame the RMP intervention for the deaths of the 2 subjects if they were never exposed to RMP. Nor does it make sense to credit RMP with curing the 3 who got better before starting the trial. The 10 in the Other group who actually read the RMP articles are a bit more troublesome, in that they were likely exposed to both conditions; however, we can again argue that the best course of action would be to drop them from the analyses, along with the 7 subjects who withdrew. On the other hand (and there's always another hand), the more subjects we drop from the analyses, the greater the possibility that we're biasing the results by deviating from random assignment. There's no easy solution to this conundrum. For therapies in which it is difficult to disentangle the beneficial effects from the side effects (for example, drug therapies), "can" and "does" may boil down to the same thing-so we should count people who dropped out. With other types of interventions, such as the talking therapies, it may be possible to alter those aspects that lead to dropping out without affecting the therapy itself (for example, by extending clinic hours or even bringing the therapy to the patient). In these situations, there may be a big difference between can and does, so it makes more sense not to count people who have dropped out.
The picture is entirely different for an effectiveness trial, in that the bind disappears-we have to count everybody. In real life, if patients become desperate and commit suicide before the treatment has had a chance to work, then that is the fault of the treatment and how it is delivered. One cannot ignore the fact that receiving therapy often involves being on a waiting list for a period of time or that the drug may not start to work for 2 or 3 weeks. Similarly, patients may discontinue a treatment because of adverse side effects, which can be anything from blurry vision caused by reading 22 articles, to the inconvenience of coming to class for an entire semester, to time lost from work. Finally, patients assigned to one treatment mode may deliberately or accidentally receive the other intervention. These are the realities of life and some of the reasons why the results of effectiveness trials are always equal to or worse, but never better, than those of efficacy studies. This last observation has been documented by Weisz, Donenberg, Han, and Weiss in a metaanalysis of child psychotherapy trials (17) . In well-controlled studies that were closer to the efficacy end of the continuum, the children in the experimental conditions scored 0.75 SD above those in the control conditions. Translated into English, this means that 77% of the kids who received the interventions did better than the average kid who was a control subject. However, in studies that were carried out in regular clinic settings (that is, closer to the effectiveness end of the continuum), this difference virtually disappeared.
Analysis
The differences in the study objectives also affects the approach to the statistical analyses. Effectiveness trials must count all the patients in the group to which they were originally assigned. This is referred to as an "intention-to-treat" analysis. As we have discussed, dropouts can jeopardize the results of effectiveness studies because we cannot assume that those who discontinued are a random subset of all the subjects (18) . Rather, they are more probably those who benefited the most or the least. Various statistical techniques have been developed-such as the Last Observation Carried Forward (LOCF), multiple imputation, or growth curve analysis-that allow subjects who miss appointments or who drop out entirely to be included in the analyses (18) .
These procedures are not required to the same degree in efficacy studies, because we are interested only in those patients who received the full course of treatment. As a consequence, we are not interested in those who discontinued early, for whatever reason, or those who were contaminated by receiving some or all of the wrong treatment. Here, imputation is used to fill in the blanks when some demographic data are missing, or if the patient skipped some appointments in the middle of the test. We would not impute data if a subject dropped out entirely.
Conclusions
Cook and Campbell differentiate between the internal validity of a study and its external validity (19) . The former refers to the design aspects of the investigation-how well it was carried out, the degree to which various biases were avoided, and whether it had minimal dropouts. Internal validity affects the degree to which we can conclude that the outcome resulted from the intervention and from other factors, such as the groups' differing on key variables or differential dropouts from the various conditions. Of equal, if not greater, concern for clinicians is the study's external validity, which affects our ability to generalize the results of the trial to the conditions that obtain in real life. Very often, there is a trade-off between these 2 types of validity: tightening up admission criteria increases internal validity at the expense of external validity, as does increasing the control over what happens during the session. "To minimize potential sources of error, we have to sacrifice verisimilitude. Conversely, the more we try to mirror the reality of the therapeutic encounter, the greater the chances are that factors outside of our control (and perhaps of our knowledge) may be responsible for the results" (20, p 117).
So, which should come first, effectiveness studies or efficacy studies? The answer is very definite: for the clinician, the most useful information comes from effectiveness studies. From this perspective, it would be wise to start with an effectiveness trial because it, and it alone, tells whether the intervention will work in real life. However, there's a risk associated with this. It is quite possible that the intervention can work, but there may have been problems in the treatment delivery-in patient selection criteria, in therapist training, in nonadherence due to side effects or the requirements of the study itself, or in other factors that led to finding no difference between the groups. This Type II error-concluding that there is no significant effect when in fact there is one-may prematurely cut off further research in the area. Had there been significant findings from a previous efficacy study, though, researchers would be more inclined to start investigating the reasons for the effectiveness study's failure, focusing on the way the therapy was delivered, rather than dismissing the treatment as ineffective.
No single study can answer all questions, and investigators must decide where they want to be on the efficacyeffectiveness spectrum. Consequently, to know more about the usefulness of an intervention, we require a series of studies, spanning the continuum from one end to the other. Les études qui vérifient l'utilité de diverses thérapies se classent dans un continuum qui va de celles qui vérifient si une intervention peut fonctionner dans des circonstances idéales (essais d'efficacité) à celles qui évaluent si un traitement fonctionne quand on l'applique au monde réel (essais d'effet utile).Qu'une étude soit plus près d'une extrémité du spectre ou de l'autre influe sur presque chaque aspect de l'essai. Ces aspects sont notamment quels patients sont admissibles à l'inscription, le degré de contrôle sur la façon dont l'intervention est exécutée, quels patients sont inclus ou non dans l'analyse, comment on tient compte des données manquantes et même quels essais statistiques peuvent être utilisés. Les deux types d'essai peuvent donner des résultats différents, mais les deux fournissent des renseignements utiles. Cet article étudie ces questions, montre les décisions que doivent prendre les chercheurs à chaque phase d'une étude et discute de la façon dont les cliniciens doivent interpréter les résultats.
